Etiological Pattern of Liver Cirrhosis: Experience at a Hospital in Southwestern Colombia
DOI:
https://doi.org/10.22516/25007440.1507Keywords:
Liver cirrhosis, causality, immunity, mordibity, prevalenceAbstract
Introduction: Liver cirrhosis is a leading cause of morbidity and mortality worldwide and in Colombia. Its most common etiologies have traditionally been chronic alcohol consumption and viral infections due to hepatitis B and C. However, recent decades have shown a shift in the etiological profile, with an increase in metabolic dysfunction–associated liver disease and autoimmune conditions.
Objective: To determine the etiology of liver cirrhosis in patients treated at a tertiary care hospital (Nariño, Colombia) during the period 2022–2023.
Methods: A cross-sectional descriptive observational study was conducted. Medical records of patients treated at Fundación Hospital San Pedro with a diagnosis of liver cirrhosis were reviewed. Statistical analysis was performed using Microsoft Excel 365, and approval was obtained from the hospital ethics committee.
Results: A total of 120 patients were analyzed, with a mean age of 66.4 years; females predominated (52.5%), and most patients were from the department of Nariño (90.83%). Clinically, 49.2% presented with ascites, 42.5% with upper gastrointestinal bleeding, and 17.5% with hepatic encephalopathy. According to the Child–Pugh classification, 39.2% were stage B and 25.8% stage C. The most frequent etiology was cryptogenic (35.8%), followed by autoimmune (25.0%) and alcohol-related (15.0%). In-hospital mortality was 11.7%.
Conclusions: Liver cirrhosis showed a predominantly cryptogenic etiological profile, with a high burden of advanced disease at diagnosis. The high frequency of autoimmune and steatosis-associated etiologies suggests a shift from the traditional etiological pattern observed in previous decades.
Downloads
References
Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open. 2020;3(2):e1920294. https://doi.org/10.1001/jamanetworkopen.2019.20294
Smith A, Baumgartner K, Bositis C. Cirrhosis: Diagnosis and management. Am Fam Physician. 2019;100(12):759-70. PMID: 31845776
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-71. Epub 2018 Sep 26. https://doi.org/10.1016/j.jhep.2018.09.014
Bejarano-Ramírez DF, Alvis-Zakzuk NJ, Carrasquilla G, Porras-Ramírez A, Vera-Torres A. Economic burden of liver disease in Colombia. Rev Colomb Gastroenterol. 2023;38(2):155-66. https://doi.org/10.22516/25007440.1007
Luján-Ramos MA, Díaz-Ramírez GS, Martínez-Casas OY, Morales-Ortíz AF, Donado-Gómez JH, Restrepo-Gutiérrez JC, et al. Caracterización de pacientes con cirrosis hepática y bacteriemia de un hospital universitario en Medellín, Colombia. Rev Colomb Gastroenterol. 2020;35(4):421-30. https://doi.org/10.22516/25007440.557
Prieto O, J. E., Sánchez P, S., Prieto, R. G., Rojas D, E. L., González, L., & Mendivelso, F. (2016). Características clínicas y descompensación en pacientes con cirrosis hepática atendidos en dos centros de hepatología en la ciudad de Bogotá D.C., 2010-2014. Revista Colombiana De Gastroenterología, 31(1), 1-8. https://doi.org/10.22516/25007440.66
Artola M, Rubino F. Etiología de la cirrosis: cambios epidemiológicos entre los periodos 1995-2002 y 2010-2017. Rev Gastroenterol Perú. 2020;50(3):245-53. https://doi.org/10.52787/JEFK3470
Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359-76. https://doi.org/10.1016/S0140-6736(21)01374-X
Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48. https://doi.org/10.1002/hep.31884
Villanueva C, Albillos A, Genescà J, Garcia-Pagán JC, Calleja JL, Aracil C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomized, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393(10181):1597-608. https://doi.org/10.1016/S0140-6736(18)31875-0
Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567-83. https://doi.org/10.3748/wjg.v21.i41.11567
Castera L, Yuen Chan HL, Arrese M, Afdhal N, Bedossa P, Friedrich-Rust M, et al. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64. https://doi.org/10.1016/j.jhep.2015.04.006
Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767-77. https://doi.org/10.1056/NEJMra1504367
Gonzalez-Chagolla A, Olivas-Martinez A, Ruiz-Manriquez J, Servín-Rojas M, Kauffman-Ortega E, Chávez-García LC, et al. Cirrhosis etiology trends in developing countries: Transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico. Lancet Reg Health Am. 2022;10:100235. https://doi.org/10.1016/j.lana.2021.100151
Vélez-Aguirre JD, Lepesqueur-Guillén L, Yepes-Barreto I. Nonalcoholic steatohepatitis: An emerging cause of cirrhosis in Colombia. Rev Colomb Gastroenterol. 2022;37(2):136-44. https://doi.org/10.22516/25007440.783
Flemming JA, Djerboua M, Groome PA, Booth CM, Terrault NA. NAFLD and alcohol-associated liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040. Hepatology. 2021;74(6):3330-44. Epub 2021 Aug 15. https://doi.org/10.1002/hep.32032
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista colombiana de Gastroenterología

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

| Article metrics | |
|---|---|
| Abstract views | 763 |
| Galley views | 331 |
| PDF Views | 305 |
| HTML views | 0 |
| Other views | 26 |














